Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
13.66
+0.07 (0.52%)
At close: May 8, 2026, 4:00 PM EDT
14.09
+0.43 (3.15%)
After-hours: May 8, 2026, 7:33 PM EDT
Generate Biomedicines Stock Forecast
Stock Price Forecast
The 5 analysts that cover Generate Biomedicines stock have a consensus rating of "Strong Buy" and an average price target of $25, which forecasts a 83.02% increase in the stock price over the next year. The lowest target is $20 and the highest is $30.
Price Target: $25 (+83.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 |
|---|---|---|
| Strong Buy | 3 | 3 |
| Buy | 3 | 3 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $25 | Strong Buy | Maintains | $16 → $25 | +83.02% | May 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +17.13% | Apr 13, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +90.34% | Mar 24, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $20 | Buy | Initiates | $20 | +46.41% | Mar 24, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $24 | Buy | Initiates | $24 | +75.70% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
31.06M
from 31.89M
Decreased by -2.62%
Revenue Next Year
35.44M
from 31.06M
Increased by 14.13%
EPS This Year
-2.01
from -4.98
EPS Next Year
-2.14
from -2.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 42.0M | 42.0M | ||||||
| Avg | 31.1M | 35.4M | ||||||
| Low | 19.6M | 23.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.7% | 35.2% | ||||||
| Avg | -2.6% | 14.1% | ||||||
| Low | -38.5% | -24.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.74 | -1.82 | |
| Avg | -2.01 | -2.14 | |
| Low | -2.14 | -2.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.